NCT05363826View on ClinicalTrials.gov

Intracavitary Photodynamic Therapy as an Adjuvant to Resection of Glioblastoma or Gliosarcoma Using IV Photobac®

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 11, 2023

Primary Completion Date

May 31, 2025

Study Completion Date

May 31, 2026

Conditions
Glioblastoma Multiforme of BrainGlioma, Sarcomatous
Interventions
COMBINATION_PRODUCT

photochemotherapy using 3-(1-Butyloxy)ethyl-3-deacetyl-bacteriopurpurin-18-n-butylimide methyl ester(Photobac®)

"Intravenous injection of Photobac® 24 hours before surgical removal of recurrent GBMF.~Immediately after resection, the cavity will be treated with 50 joules/ square cm of 787nm light. This treatment will add a maximum of 50 minutes to the surgery"

Trial Locations (1)

14263

RECRUITING

Roswell Park Cancer, Buffalo

All Listed Sponsors
collaborator

Roswell Park Cancer Institute

OTHER

collaborator

National Cancer Institute (NCI)

NIH

lead

Photolitec LLC

INDUSTRY